NIH to Grant Exclusive License for Microtubule Stabilizing Agents to Treat Atherosclerosis and Restenosis

Summary

The National Institutes of Health is considering granting a worldwide, limited field of use, exclusive license to Angiotech Pharmaceuticals to practice inventions related to treating atherosclerosis and restenosis using microtubule stabilizing agents, including Taxol (Paclitaxel), for non-cancerous uses.